Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Almac Discovery Limited maintains a company patent portfolio in the Biotechnology & Pharmaceuticals technology area. The company currently has 3 pending office actions. These actions are distributed among 3 distinct examiners, meaning each examiner is handling a single pending matter.
The portfolio spans 2 distinct art units. This indicates that while the technology is centered on biotechnology and pharmaceuticals, the specific applications or compounds are being reviewed across different specialized groups. HEITMEIER, KENDALL NICOLE is identified as the busiest examiner, with 1 busiest examiner pending office action.
Practitioners should observe that with 3 pending office actions and 3 examiners, the workload is evenly spread. The involvement of 2 art units suggests technical diversity within the pharmaceutical filings. Managing these 3 pending actions requires attention to the specific preferences of the 3 different examiners involved. This distribution ensures that no single examiner's backlog significantly delays the entire portfolio's progress.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (33%) |
| Double-patenting + other | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HEITMEIER, KENDALL NICOLE | 1 | 65.9% | +41.0% |
| REILLY, SOPHIA JANE | 1 | 60.8% | +49.2% |
| HOPKINS, SAMANTHA LAKE | 1 | 60.4% | +62.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17620819 | ANTHRACYCLINE DERIVATIVES | HOPKINS, SAMANTHA LAKE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17760329 | USP7 INHIBITOR FOR USE IN THE TREATMENT OF CANCER | REILLY, SOPHIA JANE | 22d |
| 18729403 | HETEROCYCLIC COMPOUNDS AS UBIQUITIN SPECIFIC PROTEASE 7 INHIBITORS | HEITMEIER, KENDALL NICOLE | — |
| 17620819 | ANTHRACYCLINE DERIVATIVES | HOPKINS, SAMANTHA LAKE | — |
| Art Unit | Apps |
|---|---|
| 1627 | 1 |
| 1641 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18729403 | HETEROCYCLIC COMPOUNDS AS UBIQUITIN SPECIFIC PROTEASE 7 INHIBITORS | HEITMEIER, KENDALL NICOLE | — | §103§112DP | Non-Final OA | — | Pending | Jul 16, 2024 |
| 17760329 | USP7 INHIBITOR FOR USE IN THE TREATMENT OF CANCER | REILLY, SOPHIA JANE | 1627 | §103 | Final Rejection | 22d | Pending | Aug 08, 2022 |
| 17620819 | ANTHRACYCLINE DERIVATIVES | HOPKINS, SAMANTHA LAKE | 1641 | §103§112Other | Final Rejection | — | Pending | Dec 20, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial